Taiwan Liposome
Manufacturing · Taiwan · 51-200 Employees
View Company Info for Free
Overview
Headquarters
No. 3 Yuanqu Street 11th Floor-1, Taipei...Phone Number
+886 226557377Website
www.tlcbio.comRevenue
$8.8 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Taiwan Liposome
TLC BioSciences is a biopharmaceutical company focused on developing innovative therapies for various medical conditions, including orthopedics, metabolic and immune disorders, and infectious diseases. Their proprietary technologies, such as BioSeizer and Genosphere, enable advanced drug delivery systems and next-generation treatments. The company aims to serve healthcare providers and patients by delivering effective solutions that improve health outcomes. With a commitment to research and development, TLC BioSciences is positioned to make a significant impact in the healthcare industry.Explore more
Taiwan Liposome Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Taiwan Liposome your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Taiwan Liposome is spiking on competitors!
Taiwan Liposome, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Taiwan Liposome launches new products
Click to see if Taiwan Liposome had a recent Job posting/layoffs
Check if Taiwan Liposome has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Taiwan Liposome has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Taiwan Liposome recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Taiwan Liposome
Recommended Actions
Reach out to Masked Content who joined Taiwan Liposome as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Taiwan Liposome is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Taiwan Liposome is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Taiwan Liposome.
Taiwan Liposome financials insights
Gather financial insights about Taiwan Liposome, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Share Placement
$27M
2020
Debt
$150K
Share Placement
$23M
Taiwan Liposome Tech Stack
A closer look at the technologies used by Taiwan Liposome
Most Recent Scoops
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Event
Events
Project
Partnership
Event
will be attending the 2022 BIO International Convention conference as an exhibitor. The event will occur from June 13 to June 16, 2022.
Funding
Taiwan Liposome News & Media
Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain
DUBLIN, June 13, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) has executed an agreement with Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines...TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy
TLC599 reduces pain and improves function for up to 24 weeks, longer than existing intraarticular treatments, and significantly reduces oral medication useSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have bTaiwan Liposome to file for voluntary delisting of ADSs
Taiwan Liposome to file for voluntary delisting of ADSs Seeking AlphaTLC Announces Voluntary Delisting and Deregistration of American Depositary Shares
This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The securities to be issued pursuant to the stock swap transaction will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or under any relevant securities laws of any state or other jurisdiction of the United States. Such securities
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Taiwan Liposome
Sign Up For FreeTo access detailed company insights
TLC BioSciences is a biopharmaceutical company focused on developing innovative therapies for various medical conditions, including orthopedics, metabolic and immune disorders, and infectious diseases. Their proprietary technologies, such as BioSeizer and Genosphere, enable advanced drug delivery systems and next-generation treatments. The company... Read More
